Our financials

For the last five years, UCB has delivered continuous growth and built up strong financial foundations, allowing us to:

  • Invest a substantial part of our revenue in our pipeline with R&D expenses around € 1-1.2 billion
  • Increase our financial flexibility by bringing our debt down: net debt / rEBITDA ratio has decreased from 2.65 in 2014 to 0.17 in 2018
  • To reach peer profitability with a rEBITDA / revenue ratio which has increased from 18% in 2014 to 30% in 2018.

I think the more education we can do, the more minds we can open. As more minds open, then more doors can open for people with epilepsy.

Monica, living with epilepsy

Delivering continuous profitable growth


Recurring EBITDA

Core EPS

Strong foundations for future growth

Lut, living with osteoporosis